An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Patients (Male or Female ≥18 Years) With Ph + CML in Blast Crisis

Mise à jour : Il y a 4 ans
Référence : NCT00171158

Femme et Homme

Extrait

This extension II study will allow for further follow-up of the disease under treatment with imatinib mesylate and allow the patients to continue to receive imatinib mesylate.


Critère d'inclusion

  • Philadelphia Positive Chronic Myeloid Leukemia in Myeloid Blast Crisis


Liens